Learn how to contact trace COVID-19 with UH's new, online course. Photo by Getty Images

As the nationwide battle against COVID-19 surges on, the University of Houston is launching a free new program to train locals how to identify and warn potentially exposed individuals throughout the region.

The new contact tracing and case identification certificate program — dubbed Epi Corps for Epidemiology Corps — is meant to train up a new type of so-called "disease detective" to combat coronavirus. The 12-hour, online course is currently open to UH students, faculty, and staff — and will soon be made available to the general public, according to the university.

This comes as the Houston Health Department last week announced plans to add 300 new contact tracers in addition to the 300 disease detectives Harris County Public Health plans to recruit. More than 100,000 trained contact tracers will be needed across the country to address COVID-19, according to a report by Johns Hopkins University. Texas Gov. Greg Abbott's plan to reopen the state calls for some 4,000 contact tracers to be hired statewide by mid-May.

The goal for the Epi Corps training program is to be scaled statewide, as Texas lags in per-capita testing for coronavirus, ranking 47th out of 50 states. "We really do not have a good handle on how many people have been exposed or how many people are asymptomatic carriers, making contact tracing critically important," said program organizer, Bettina Beech, in a statement.

Contact tracing is considered crucial in the fight against COVID-19, teamed with social distancing, stay-at-home mandates, and good hygiene practices. The Center for Disease Control warns if communities are unable to effectively isolate patients and ensure contacts can separate themselves from others, rapid community spread of COVID-19 is likely to increase to the point that strict mitigation strategies will again be needed to contain the virus.

Through this new program, the corps staffers could be deployed to work on-site at the city and county health departments to assist COVID-19 patients recall everyone they've had close contact with leading up to their infection. The contact tracers would then notify those contacts of their potential exposure and provide education, support, and information to understand their risk.

The contact tracers-in-training will be trained on COVID-19 signs and symptoms, epidemiology, medical terminology, cultural competency, interpersonal communication and interviewing skills, patient confidentiality, and more, according to the school. Those who successfully complete the course will receive a digital certificate, and some students will be eligible to earn credit hours.

The Epi Corps curriculum will be administered via the Blackboard digital learning platform. Plans are moving forward to make a shorter program available to the community at large, including small businesses, in the coming weeks.

The training follows a format similar to the Centers for Disease Control and Prevention contact tracing training program for tuberculosis and is based on the Association of State and Territorial Health Officials contact tracing training modules, according to UH.

"Contact tracing, along with large-scale testing, is a critical component to reopening our state and to stimulate the economy, but the national and local public health infrastructure does not have the capacity to handle this task alone," said Dr. Stephen Spann, founding dean of the UH College of Medicine, in a statement. "As a public university dedicated to serving the community, it's incumbent upon us to step up and provide the necessary training so we can get through this crisis together."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.